Literature DB >> 3405782

[Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses].

E Moser1, C R Pickardt, K Mann, D Engelhardt, C M Kirsch, P Knesewitsch, K Tatsch, T Kreisig, C Kurz, B Saller.   

Abstract

The aim of this study was to check the efficacy of radioiodine (131I) therapy (RIT) in a large number of patients (n = 506) suffering from immunogenic or non-immunogenic hyperthyroidism (Graves' disease, Plummer's disease). Since there is no causal cure for immunogenic hyperthyroidism RIT provides, like all other modalities, only a moderate rate of success which is clearly dose-related. Applying 60 Gy, normal thyroid function can be achieved in only 54% of the cases. A dose of 150 Gy succeeds in 86% of the cases. The solitary decompensated autonomous adenoma (DAA) can be eliminated surgically as well as by RIT with a high degree of success (95%). Contrary to surgery, RIT does not have any noticeable early or late morbidity. The high rate of success of RIT in patients with DAA could be confirmed in two groups with different follow-up periods (16 and 65 months). As expected, the rate of hypothyroidism increased from 11% in the early group to 23% in the late group. Multinodular autonomous adenomas can be eliminated successfully using RIT as well. The concept to apply a dose of 400 Gy to the total functional autonomous tissue as determined by ultrasound yields better results (95%) than 150 Gy to the whole thyroid gland as measured by ultrasound (88%). The rate of hypothyroidism as shown by these results (up to a maximum of 62% after RIT of Graves' disease using 150 Gy) is the lesser evil compared to remaining or recurrent hyperthyroidism since these patients can be treated with thyroid hormones without problems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3405782

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  9 in total

1.  [Epidemiology, pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules].

Authors:  Ralf Paschke; Kurt Werner Schmid; Roland Gärtner; Klaus Mann; Henning Dralle; Christian Reiners
Journal:  Med Klin (Munich)       Date:  2010-02-20

Review 2.  [Diagnosis and therapy of thyroid nodules].

Authors:  A Tönjes; R Paschke
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

3.  Value of ethanol injection in the treatment of the autonomous thyroid nodule.

Authors:  C Ferrari
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 4.  [Therapy of thyroid gland autonomy].

Authors:  W Becker
Journal:  Klin Wochenschr       Date:  1990-06-19

5.  [Radioiodine therapy of functional autonomy of the thyroid gland. Treatment results in view of pretreatment scintigraphic diagnosis and early response of triiodothyronine levels to treatment].

Authors:  H R Langhammer; C Laubenbacher; C Hirsch; C Klingele; J L Spyra; R Senekowitsch-Schmidtke; M Schwaiger
Journal:  Med Klin (Munich)       Date:  1999-08-15

6.  [Early changes in thyroid hormones following radioiodine therapy of hyperthyroidism with reference to etiology and accompanying medication].

Authors:  T Kreisig; W Abenhardt; K Mann; C M Kirsch; E Moser
Journal:  Klin Wochenschr       Date:  1989-04-03

7.  Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre.

Authors:  D A Huysmans; A R Hermus; F H Corstens; P W Kloppenborg
Journal:  Eur J Nucl Med       Date:  1993-11

8.  Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease.

Authors:  U F Willemsen; P Knesewitsch; T Kreisig; C R Pickardt; C M Kirsch
Journal:  Eur J Nucl Med       Date:  1993-11

9.  A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism.

Authors:  Suhail AR Doi; Issa Loutfi; Kamal AS Al-Shoumer
Journal:  BMC Nucl Med       Date:  2001
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.